SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-006087
Filing Date
2024-02-13
Accepted
2024-02-13 16:15:37
Documents
15
Period of Report
2024-02-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40234
2 ex99-1.htm EX-99.1 35831
  Complete submission text file 0001493152-24-006087.txt   259485

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE aneb-20240213.xsd EX-101.SCH 3012
4 XBRL LABEL FILE aneb-20240213_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE aneb-20240213_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3929
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 24626100
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)